Journal Club
Open Access Article

Putting Evidence Into Practice: What Are the Pharmacologic Interventions for Nociceptive and Neuropathic Cancer Pain in Adults?

Lisa B. Aiello-Laws

Janice Reynolds

Nancy Deizer

Mary E. Peterson

Suzanne A. Ameringer

Marie Bakitas
neuropathic pain, evidence-based practice
CJON 2009, 13(6), 649-655. DOI: 10.1188/09.CJON.649-655

Cancer pain continues to be undertreated in adults despite the substantial amount of research on pain management. The Oncology Nursing Society coordinated a team for the Putting Evidence Into Practice (PEP) project to develop (and update) a PEP resource summarizing the current evidence for the pharmacologic management of adults with nociceptive and neuropathic cancer pain. The aim of this article is to describe the development process and outcomes of the project. The review established that long-acting opioids in conjunction with immediate-release opioids are recommended for practice; radionuclides and radioisotopes as useful adjuncts for metastatic bone pain are likely to be effective; the effectiveness of tetrodotoxin, a neurotoxin, is not yet established; and spinal opioids, caffeine, or sympatholytic agents have beneficial and harmful effects and should be considered on an individual basis. Pain is a nursing-sensitive patient outcome; that is, pain can be directly affected by nursing interventions. Knowing the current evidence for pharmacologic management of cancer pain is critical to improve patient outcomes.

Jump to a section


    American Geriatrics Society. (2002). Clinical practice guidelines: The management of persistent pain in older persons. Journal of the American Geriatrics Society, 50(6, Suppl.), S205-S224.

    American Pain Society. (2005). Guideline for the management of cancer pain in adults and children. Glenview, IL: Author.

    Auret, K., Roger Goucke, C., Ilett, K.F., Page-Sharp, M., Boyd, F., & Oh, T.E. (2006). Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. Therapeutic Drug Monitoring, 28(3), 359-366.

    Baczyk, M., Czepczynski, R., Milecki, P., Pisarek, M., Oleksa, R., & Sowinski, J. (2007). 89Sr versus 153Sm-EDTMP: Comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nuclear Medicine Communications, 28(4), 245-250.

    Ballantyne, J.C., & Carwood, C.M. (2005). Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer. Cochrane Database of Systematic Reviews, 1, CD005178.

    Bell, R., Eccleston, C., & Kalso, E. (2003). Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database of Systematic Reviews, 1, CD003351.

    Centeno, C., & Vara, F. (2005). Intermittent subcutaneous methadone administration in the management of cancer pain. Journal of Pain and Palliative Care Pharmacotherapy, 19(2), 7-12.

    Challapalli, V., Tremont-Lukats, I.W., McNicol, E.D., Lau, J., & Carr, D.B. (2005). Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database of Systematic Reviews, 4, CD003345.

    Colella, J., Scrofine, S., Galli, B., Knorr-Mulder, C., Gejerman, G., Scheuch, J., et al. (2006). Prostate HDR radiation therapy: A comparative study evaluating the effectiveness of pain management with peripheral PCA vs. PCEA. Urologic Nursing, 26(1), 57-61.

    Currow, D. C, Plummer, J.L., Conney, N.J., Gorman, D., & Glare, P.A. (2007). A randomized, double-blind, multi-site, crossover, placebo-controlled equivalence study of morning versus evening once-daily sustained-release morphine sulfate in people with pain from advanced cancer. Journal of Pain and Symptom Management, 34(1), 17-23.

    Darwish, M., Kirby, M., Robertson, P., Tracewell, W., & Jiang, J.G. (2007). Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: A pilot study. Clinical Drug Investigation, 27(9), 605-611.

    Dudgeon, D.J., Bruera, E., Gagnon, B., Watanabe, S.M., Allan, S.J., Warr, D.G., et al. (2007). A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients. Journal of Pain and Symptom Management, 33(4), 365-371.

    Dunteman, E.D. (2005). Levetiracetam as an adjunctive analgesic in neoplastic plexopathies: Case series and commentary. Journal of Pain and Palliative Care Pharmacotherapy, 19(1), 35-43.

    Dworkin, R.H., O'Connor, A.B., Backonja, M., Farrar, J.T., Finnerup, N.B., Jensen, T.S., et al. (2007). Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain, 132(3), 237-251.

    Elsner, F., Radbruch, L., Loick, G., Gartner, J., & Sabatowski, R. (2005). Intravenous versus subcutaneous morphine titration in patients with persisting exacerbation of cancer pain. Journal of Palliative Medicine, 8(4), 743-750.

    Glare, P., Walsh, D., & Sheehan, D. (2006). The adverse effects of morphine: A prospective survey of common symptoms during repeated dosing for chronic cancer pain. American Journal of Hospice and Palliative Medicine, 23(3), 229-235.

    Grosset, A.B., Roberts, M.S., Woodson, M.E., Shi, M., Swanton, R.E., Reder, R.F., et al. (2005). Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: Two randomized controlled trials. Journal of Pain and Symptom Management, 29(6), 584-594.

    Hagen, N.A., du Souich, P., Lapointe, B., Ong-Lam, M., Dubuc, B., Walde, D., et al. (2008). Tetrodotoxin for moderate to severe cancer pain: a randomized, double blind, parallel design multicenter study. Journal of Pain and Symptom Management, 35(4), 420-429.

    Hagen, N.A., Fisher, K., Victorino, C., & Farrar, J.T. (2007). A titration strategy is needed to manage breakthrough cancer pain effectively: Observations from data pooled from three clinical trials. Journal of Palliative Medicine, 10(1), 47-55.

    Hagen, N.A., Fisher, K.M., Lapointe, B, du Souich, P., Chary, S., Moulin, D., et al. (2007). An open-label, multi-dose efficacy and safety study of intramuscular tetrodotoxin in patients with severe cancer-related pain. Journal of Pain and Symptom Management, 34(2), 171-182.

    Holmes Gobel, B., Beck, S., & O'Leary, C. (2006). Nursing-sensitive patient outcomes: The development of the Putting Evidence Into Practice resources for nursing practice. Clinical Journal of Oncology Nursing, 10(5), 621-624.

    Keskinbora, K, Pekel, A.F., & Aydinli, I. (2007). Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: A randomized open trial. Journal of Pain and Symptom Management, 34(2), 183-189.

    Komurcu, S., Turhal, S., Altundag, K., Atahan, L., Turna, H.S., Manavoglu, O., et al. (2007). Safety and efficacy of transdermal fentanyl in patients with cancer pain: Phase IV, Turkish oncology group trial. European Journal of Cancer Care, 16(1), 67-73.

    Koshy, R.C., Kuriakose, R., Sebastian, P., & Koshy, C. (2005). Continuous morphine infusions for cancer pain in resource-scarce environments: Comparison of the subcutaneous and intravenous routes of administration. Journal of Pain and Palliative Care Pharmacotherapy, 19(1), 27-33.

    Liepe, K., & Kotzerke, J. (2007). A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nuclear Medicine Communications, 28(8), 623-630.

    Maltoni, M., Scarpi, E., Modonesi, C., Passardi, A., Calpona, S., Turriziani, A., et al. (2005). A validation study of the WHO analgesic ladder: A two-step vs. three-step strategy. Supportive Care in Cancer, 13(11), 888-894.

    Marinangeli, F., Ciccozzi, A., Aloisio, L., Colangeli, A., Paladini, A., Bajocco, C., et al. (2007). Improved cancer pain treatment using combined fentanyl-TTS and tramadol. Pain Practice, 7(4), 307-312.

    Martinez-Zapata, M.J., Roque, M., Alonso-Coello, P., & Catala, E. (2006). Calcitonin for metastatic bone pain. Cochrane Database of Systematic Reviews, 3, CD003223.

    Mercadante, S., Arcuri, E., Ferrera, P., Villari, P., & Mangione, S. (2005). Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. Journal of Pain and Symptom Management, 30(5), 485-491.

    Mercadante, S., Arcuri, E., Fusco, F., Tirelli, W., Villari, P., Bussolino, C., et al. (2005). Randomized double-blind, double-dummy crossover clinical trial of oral tramadol versus rectal tramadol administration in opioid-naive cancer patients with pain. Supportive Care in Cancer, 13(9), 702-707.

    Mercadante, S., Villari, P., Ferrera, P., & Casuccio, A. (2006). Opioid-induced or pain relief-reduced symptoms in advanced cancer patients? European Journal of Pain, 10(2), 153-159.

    Mercadante, S., Villari, P., Ferrera, P., Casuccio, A., Mangione, S., & Intravaia, G. (2007). Transmucosal fentanyl versus intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. British Journal of Cancer, 96(12), 1828-1833.

    Moryl, N., Kogan, M., Comfort, C., & Obbens, E. (2005). Methadone in the treatment of pain and terminal delirium in advanced cancer patients. Palliative and Supportive Care, 3(4), 311-317.

    National Comprehensive Cancer Network. (2008). NCCN Clinical Practice Guidelines in Oncology™: Adult cancer pain [v.1.2008]. Retrieved October 29, 2008, from

    Nicholson, A.B. (2007). Methadone for cancer pain. Cochrane Database of Systematic Reviews, 3, CD003971.

    Novartis Pharmaceuticals. (2008). Aredia® (pamidronate disodium for injection) [Package insert]. Retrieved October 29, 2009, from

    Pan, H., Zhang, Z., Zhang, Y., Xu, N., Lu, L., Dou, C., et al. (2007). Efficacy and tolerability of oxycodone hydrochloride controlled-release tablets in moderate to severe cancer pain. Clinical Drug Investigations, 27(4), 259-267.

    Pergolizzi, S., Iati, G., Santacaterina, A., Palazzolo, C., Di Pietro, A., Garufi, G., et al. (2006). Treatment planning in patients with bone metastases. Final results of a prospective study using pre-medication with fentanyl to improve irradiation reproducibility. Supportive and Palliative Cancer Care, 2(2), 71-75.

    Pfizer Inc. (2009). Celebrex® (celecoxib) [Package insert]. Retrieved October 29, 2009, from

    Reid, C.M., Martin, R.M., Sterne, J.A., Davies, A.N., & Hanks, G.W. (2006). Oxycodone for cancer-related pain: Meta-analysis of randomized controlled trials. Archives of Internal Medicine, 166(8), 837-843.

    Roque, M., Martinez-Zapata, M.J., Alonso, P., Catala, E., Garcia, J.L., & Ferrandiz, M. (2003). Radioisotopes for metastatic bone pain. Cochrane Database of Systematic Reviews, 4, CD003347.

    Ross, J.R., Goller, K., Hardy, J., Riley, J., Broadley, K., A'hern, R., et al. (2005). Gabapentin is effective in the treatment of cancer-related neuropathic pain: A prospective, open-label study. Journal of Palliative Medicine, 8(6), 1118-1126.

    Sartor, O., Reid, R.H., Bushnell, D.L., Quick, D.P., & Ell, P.J. (2007). Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer, 109(3), 637-643.

    Smith, T.J., & Coyne, P.J. (2005). Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients. Journal of Palliative Medicine, 8(4), 736-742.

    Solassol, I., Caumette, L., Bressolle, F., Garcia, F., Thezenas, S., Astre, C., et al. (2005). Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients. Oncology Reports, 14(4), 1029-1036.

    Stearns, L., Boortz-Marx, R., Du Pen, S., Friehs, G., Gordon, M., Halyard, M., et al. (2005). Intrathecal drug delivery for the management of cancer pain: A multidisciplinary consensus of best clinical practices. Journal of Supportive Oncology, 3(6), 399-408.

    Tassinari, D., Sartori, S., Tamburini, E., Scarpi, E., Raffaeli, W., Tombesi, P., et al. (2008). Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: A meta-analysis and systematic review of the literature. Journal of Palliative Medicine, 11(3), 492-501.

    Wallace, M., Rauck, R.L., Moulin, D., Thipphawong, J., Khanna, S., & Tudor, I.C. (2008). Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain. Journal of International Medical Research, 36(2), 343-352.

    Weinbroum, A.A. (2005). Superiority of postoperative epidural over intravenous patient-controlled analgesia in orthopedic oncologic patients. Surgery, 138(5), 869-876.

    Wiffen, P.J., McQuay, H.J. (2007). Oral morphine for cancer pain. Cochrane Database of Systematic Reviews, 4, CD003868.

    Wong, R., & Wiffen, P.J. (2002). Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database of Systematic Reviews, 2, CD002068.

    Woolery, M., Bisanz, A., Lyons, H.F., Gaido, L., Yenulevich, M., Fulton, S., et al. (2008). Putting Evidence Into Practice: Evidence-based interventions for the prevention of management of constipation in patients with cancer. Clinical Journal of Oncology Nursing, 12(2), 317-337.

    Wootten, M. (2004). Morphine is not the only analgesic in palliative care: Literature review. Journal of Advanced Nursing, 45(5), 527-532.

    Yuen, K.K., Shelley, M., Sze, W.M., Wilt, T., & Mason, M.D. (2006). Bisphosphonates for advanced prostate cancer. Cochrane Database of Systematic Reviews, 4, CD006250.

    Zeppetella, G., & Ribeiro, M.D. (2006). Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database of Systematic Reviews, 1, CD004311.